As the recent reshoring zeal rolls on in the United States, BeOne Medicines is beefing up its flagship manufacturing and R&D campus in New Jersey to the tune of $300 million.
The outlay at the site at the Princeton West Innovation Campus in Hopewell helps lift the company’s total U.S. production commitment to more than $1 billion and comes as the persistent threat of import tariffs and drug pricing reform by the Trump administration has sparked a wave of similar pharma investments since 2025.
The upgrade to the facility is expected to create 120 new manufacturing jobs once complete.
BeOne—which formerly operated under the moniker BeiGene—said the project will add small molecule manufacturing capacity at the Hopewell site, which has until now only boasted biologics production capabilities.
The buildout will include a new three-story, 145,000-square-foot building for drug product manufacturing and packaging adjacent to BeOne’s current Hopewell facilities, driving the eventual footprint of the site to 545,000 square feet, the cancer drugmaker said in a July 23 release.
The building will also incorporate quality control labs, office space and capacity set aside for future growth, BeOne added. BeOne said it expects the expansion to be fully operational by 2029, with an estimated total headcount of 240 workers once small molecule operations have kicked off.
BeOne uses its New Jersey site, which opened in the summer of 2024, both for commercial and clinical-stage manufacturing across its solid tumor portfolio.
The facility is BeOne’s only manufacturing site in the U.S. and one of three globally, standing alongside two others in Guangzhou and Suzhou in China.
“Today's announcement reflects BeOne's commitment to strengthening U.S. manufacturing and expanding access to innovative medicines for patients with cancer,” Aaron Rosenberg, BeOne’s chief financial officer, said in a statement.
He continued, “We appreciate the federal tax policies advanced by the President that encourage investment in biopharmaceutical production, alongside the Next New Jersey Manufacturing Program and the Governor’s efforts to support advanced manufacturing and high-quality job creation,” adding that these factors “create an environment for long-term growth.”
BeOne is among many other pharma heavyweights flexing their commitment to U.S. manufacturing and R&D since President Donald Trump took office for his second term.
A combination of tariff threats and drug pricing demands have helped the administration extract prominent investment pledges from 17 large drugmakers.
BeOne sought to emphasize the importance of the U.S. to its work in Thursday’s announcement.
Of the 12,000 people it employs around the world, more than 2,000 are located in the U.S., and the company claims it helped generated nearly $2 billion in direct U.S. economic impact in 2025, alongside roughly $1 billion in domestic R&D investment. BeOne is officially domiciled in Switzerland.